** Medical equipment maker TransMedics' TMDX.O shares rise 4.4% to $75 premarket
** Co's Q4 revenue of $121.6 million beats analysts' average expectation of $110.3 million, according to data compiled by LSEG
** TMDX forecasts annual revenue between $530 mln and $552 mln, the midpoint of which is above analysts' average estimate of $539 mln - LSEG
** Up to last close, stock down 18.7% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。